Biora Therapeutics, Inc.

Biora reported Q2 2024 operating expenses, excluding stock-based compensation, of $14.5 million, including G&A of $7.5 million and R&D of $7 million; core OpEx was $11.7 million. The company said net income was $6.5 million for the quarter, helped by noncash items such as derivative and warrant liability changes. On the clinical side, management said BT-600 achieved a PK profile consistent with colon delivery, with systemic levels three to four times lower than conventional oral delivery, drug detected across all three distal-colon biopsy sites, and greater than 95% accuracy of release in the colon with no early release before colon entry. Forward-looking items include presenting BT-600 data at the American College of Gastroenterology Annual Meeting in October, initiating a UC patient study toward the end of the year, and staying on track for a BioJet partnership in 2024. The company also announced a capital raise that adds $16 million from noteholders in $4 million increments as needed.

Adi Mohanty framed the quarter as a meaningful validation point for both platforms. On NaviCap/BT-600, he emphasized that the Phase I trial showed direct topical colon delivery, lower systemic exposure, and tissue levels above IC50 despite low doses and late biopsies, and he said the goal is to break what he called the therapeutic ceiling in ulcerative colitis. On BioJet, he said performance continues to exceed targets and that partnership discussions are narrowing, with management hopeful of closing at least one near term and still aiming for a 2024 partnership.

Eric d'Esparbes focused on cash support and expense structure. He said Q2 operating expenses excluding stock-based compensation were $14.5 million, with $7.5 million of G&A and $7 million of R&D, and noted that about 40% of G&A was tied to legacy matters that management wants to eliminate by year-end. He also highlighted a $16 million capital commitment from existing noteholders, delivered in $4 million tranches, and described the transaction as a bridge to an anticipated pharma partnership. He added that the structure includes a significant equity component through convertible features and warrants.

Analysts asked how the BioJet partnership talks are evolving, and management said the discussions started broadly but are now narrowing, including how to work with potentially more than one partner. On BT-600, questions focused on how the direct-to-colon delivery differs from conventional oral dosing; management said the key advantage is higher tissue exposure with much lower systemic exposure, which could help avoid the toxicity seen when oral JAK inhibitor doses are pushed higher. Another question asked about how much of the payload may pass through unabsorbed, and management said it has some of that information, that the majority is absorbed in the colon, and that more data will be shared later. For manufacturing, management said it has contract manufacturers and internal capability to make a handful now, several hundred already, and several thousand in the short period, with automation being built for larger scale later.